TELUS Health：2025年加拿大药物研发管线：私人药物保险计划机遇与挑战研究报告（英文版）（25页）.pdf

1、Drug Pipeline:What private plans need to know.2025 March 20252P.l 2025 Drug PipelineContentsIntroduction .3 Alzheimers disease .4 Plaque psoriasis .8 Whats old is new again.10 Migraine.11 Attention deficit hyperactivity disorder.12 Macular edema due to uveitis.12Weight management .13 2025 new drug p

2、ipeline summary.15 Generics .17 Biosimilars .20 Conclusion .23 3P.l 2025 Drug PipelineIntroductionVicky Lee,RPh,BScPhm,MMI,BSc.HonsDirector,Pharmacy Consulting&Professional Services Payor Solutions,TELUS HealthAt the start of this year,approximately 17,700 drugs were under development in Canada,down

3、 slightly from the 18,000 reported at the start of 2024 but still well ahead of the 16,200 reported in 2023.About one in six this year(2,900)are in the final,phase-3 stage of development.From this large pool of potential new medications,fewer than 200 will make it to Health Canada for regulatory rev

4、iew.Health Canada is currently evaluating 159 submissions,up somewhat from the previous two years at this point(120 in 2024 and 123 in 2023)and comparable to 2022(142)and 2021(150).Just over half of this years submissions(58 per cent)are for new drugs,consistent with the previous four years,and the

5、remaining submissions are for new or expanded indications for drugs already on the market.The 2025 Drug Pipeline report takes a closer look at 10 new drugs to consider their anticipated impact on private drug plans and workplace productivity,including two breakthrough medications for Alzheimers dise

6、ase.Other new medications of interest to plan sponsors are in the areas of psoriasis,migraine and attention deficit hyperactivity disorder.The report also provides an update on three upcoming drugs for weight management,although none have yet been submitted to Health Canada for review.The 2025 editi